Upsher-Smith Launches Fluphenazine Hydrochloride Tablets


Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Fluphenazine Hydrochloride Tablets, USP in 1 mg, 2.5 mg, 5 mg, and 10 mg strengths. The fluphenazine hydrochloride tablet market had U.S. sales of approximately $30 million for the 12 months ending January 2023 according to IQVIA.Fluphenazine Hydrochloride Tablets are a generic version of the brand product, Prolixin.*

Product Information

Product Information

For questions about ordering, please call Upsher-Smith at 1-800-654-2299.

Please refer to the full Prescribing Information, including Boxed Warning for Fluphenazine Hydrochloride Tablets, USP here. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information. You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting


About Upsher-Smith

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings brands and generics to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit

*Prolixin is a registered trademark of E.R. Squibb & Sons, Inc. Prolixin Tablets have been discontinued.

SOURCE: Upsher-Smith

Related Videos
© 2024 MJH Life Sciences

All rights reserved.